Published:
eResearchTechnology, Inc. and nSpire Health, Inc. Form Alliance to Deliver Integrated Cardiac Safety and Pulmonary Clinical Trial Services
PHILADELPHIA, April 14 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc.
(eRT), (Nasdaq: ERES), and nSpire Health, Inc. announced today their alliance
to provide integrated Cardiac Safety and Pulmonary Core Lab Services to
clinical researchers worldwide.
eResearchTechnology is a leading provider of centralized
electrocardiographic (ECG), eClinical technology, ePRO, and other services to
the pharmaceutical, biotechnology, medical device, and related industries.
nSpire Health is a leading provider of respiratory clinical trials services,
including Cardiopulmonary Exercise Testing, High Definition Pulmonary
Diagnostics Systems, Spirometry, and Home Monitoring.
Under the agreement, eRT and nSpire will deliver a combined solution to
meet the increased demand for cardio-pulmonary safety and efficacy services
during clinical trials, in part caused by an increased interest in using
inhaled therapeutics. The partnership will offer integrated services from
project planning and set-up through study conduct, management, and data
delivery for primary and secondary Cardiac and Respiratory clinical trial
endpoints. nSpire Health will provide eSP(TM) Core Lab Data Management
software, QA services, HDpft(TM), KoKo(R), PiKo(R), and PiKoLogic(TM)
(electronic Diary) respiratory diagnostic measuring instruments. eRT will
perform digital collection, measurement, interpretation, review, and
distribution of cardiac safety data through its EXPeRT 2.0 workflow-enabled
data management system.
"This alliance addresses a growing need in clinical research to offer
comprehensive, best in class services in these two closely related areas of
clinical study," said Michael McKelvey, President and CEO of eRT. "While many
sponsors recognize and source each company for its respective area of
expertise, customers increasingly seek consolidation and streamlining in all
phases of a clinical trial. eRT and nSpire Health approach the market in the
same way -- focusing on scientific excellence, providing a quality product,
and client satisfaction. We are both metrics driven and process oriented to
ensure on-time, on-budget, reliable data delivery on a global scale."
"Clinical trial sponsors have a strategic need to deliver accurate, cost-
effective results in less time. They need therapeutic specialists that they
can trust. This partnership leverages the world's most advanced Cardio-
Respiratory specific technologies and data management services from each
company into one unified source, reducing costs and accelerating time to
market for emerging inhaled therapeutic trials," commented Michael S. Sims,
President and CEO of nSpire Health, Inc.
About nSpire Health
nSpire Health develops and manufactures respiratory care products and
provides related services in over 100 countries. The company is focused on
cardiopulmonary diagnostics, respiratory core lab services, and disease
management solutions designed to improve health care productivity while
increasing the overall quality of patient care. nSpire Health is the exclusive
provider of PiKo(R) home health monitors and HDpft(TM) systems, the most
accurate and precise pulmonary function testing systems worldwide.
About eRT
Based inPhiladelphia, Pa, eResearchTechnology, Inc. (www.eRT.com) is a
provider of technology and services to the pharmaceutical, biotechnology and
medical device industries on a global basis. The company is a market leader in
providing centralized core-diagnostic electrocardiographic (ECG) technology
and services to evaluate cardiac safety in clinical development. The company
is also a leader in providing technology and services to streamline the
clinical trials process by enabling its customers to automate the collection,
analysis and distribution of clinical data in all phases of clinical
development.
Statements included in this release may constitute forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995. Such statements, including, but not limited to, 2008 financial
guidance, involve a number of risks and uncertainties such as the Company's
ability to obtain new contracts and accurately estimate net revenues due to
uncertain regulatory guidance, variability in size, scope and duration of
projects, and internal issues at the sponsoring client, integration of
acquisitions, competitive factors, technological development, and market
demand. As a result, actual results may differ materially from any financial
outlooks stated herein. Further information on potential factors that could
affect the Company's financial results can be found in the Company's Reports
on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The
Company undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events, or
otherwise.
SOURCE eResearchTechnology, Inc.
Copyright © 2009, PRNewswire
Copyright © 2009, NewsBlaze,
Daily News
Tags: ,BIO,HEA,MTC,JVN,PA-eResearch-nSpire